Unimed's nitazoxanide for Cryptosporidium parvum in AIDS patients starts Phase II.
UNIMED NITAZOXANIDE FOR CRYPTOSPORIDIUM PARVUM IN AIDS PATIENTS begins Phase II trial that will include 298 patients, Buffalo Grove, Ill.-based Unimed Pharmaceuticals announced Sept. 19. Unimed, which co-markets its Marinol (dronabinol) for AIDS wasting with Roxane Labs, said the NTZ trial will be conducted at Cornell Medical Center, New York City. The principal investigator, Rosemary Soave, MD, is an "internationally known" Cryptosporidium expert, Unimed said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth